Phase 3 Study Demonstrates Aranesp® (Darbepoetin Alfa) Reduces Red Blood Cell Transfusions In Patients With Myelodysplastic Syndrome (MDS)

First Phase 3 Data From Placebo-Controlled Study With an Erythropoiesis-Stimulating Agent (ESA) in Anemic Patients With MDS Study Met Primary Endpoint and Key Secondary Endpoint of Erythroid Response THOUSAND OAKS, Calif., Feb. 15, 2016 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the randomized, double-blind, placebo-controlled Phase 3 Aranesp® (darbepoetin alfa) ARCADE trial met its primary endpoint of reducing the incidence of red blood cell transfusions in anemic patients with low and intermediate-1 risk MDS at the end of the blinded 25-week study period. Aranesp also significantly improved erythroid response, a key measure of the formation of new red blood cells. Deta...
Source: Amgen News Release - Category: Pharmaceuticals Tags: Uncategorized Source Type: news